The DLX4 antibody is a crucial tool for studying the DLX4 (Distal-less homeobox 4) protein, a member of the Distal-less (Dlx) gene family involved in embryonic development and cellular differentiation. DLX4. a homeodomain transcription factor, plays roles in regulating gene expression during embryogenesis, particularly in craniofacial, limb, and hematopoietic system development. In cancer biology, DLX4 is frequently overexpressed in malignancies such as breast, ovarian, and prostate cancers, where it is linked to tumor progression, metastasis, and chemoresistance. It modulates pathways related to cell proliferation, apoptosis, and epithelial-mesenchymal transition (EMT). DLX4 antibodies enable the detection and localization of this protein in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Researchers utilize these antibodies to explore DLX4's functional roles, its interaction with signaling pathways (e.g., Wnt/β-catenin), and its potential as a biomarker or therapeutic target. Specificity and validation of DLX4 antibodies are critical, often confirmed using knockout controls or siRNA-mediated silencing. While its dual roles in development and disease remain under investigation, DLX4 antibodies remain pivotal for unraveling its contributions to both normal physiology and pathological states, including cancer and placental disorders.